What Propel Bio Management, LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1969764 · Filed Aug 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 4M |
| New |
| $26.3M |
| 13.8% |
CORTCorcept Therapeutics Inc | 136.5K | New | $11.9M | 6.2% |
PHATPhathom Pharmaceuticals, Inc. | 1.1M | New | $11.4M | 6% |
DCTHDelcath Systems, Inc. | 871.5K | New | $11M | 5.7% |
MISTMilestone Pharmaceuticals Inc. | 7.4M | New | $10M | 5.2% |
CMPSCOMPASS Pathways plc | 573.1K | New | $8.1M | 4.2% |
KYTXKyverna Therapeutics, Inc. | 883.2K | New | $7.9M | 4.1% |
ARTVArtiva Biotherapeutics, Inc. | 696.4K | New | $6.8M | 3.5% |
ABEOAbeona Therapeutics Inc. | 983.1K | New | $6.1M | 3.2% |
AQSTAquestive Therapeutics, Inc. | 1.4M | New | $6M | 3.1% |
PALIPalisade Bio, Inc. | 2.6M | New | $5.4M | 2.8% |
IMUXImmunic, Inc. | 325K | New | $5M | 2.6% |
IVAInventiva S.A. | 1.3M | New | $4.8M | 2.5% |
SABSSAB Biotherapeutics, Inc. | 1.1M | New | $4.2M | 2.2% |
OBIOOrchestra BioMed Holdings, Inc. | 896.7K | New | $3.9M | 2% |
CLDXCelldex Therapeutics, Inc. | 103.7K | New | $3.9M | 2% |
ZVRAZevra Therapeutics, Inc. | 253.5K | New | $3.6M | 1.9% |
OCULOcular Therapeutix, Inc | 358K | New | $3.5M | 1.8% |
FDMT4D Molecular Therapeutics, Inc. | 252.7K | New | $3.4M | 1.8% |
OVIDOvid Therapeutics Inc. | 1.1M | New | $3M | 1.6% |
EYPTEyePoint, Inc. | 191.7K | New | $2.7M | 1.4% |
UPBUpstream Bio, Inc. | 350.4K | New | $2.4M | 1.3% |
SCYXScynexis Inc | 543.5K | New | $2.2M | 1.2% |
SLNSilence Therapeutics plc | 191.7K | New | $2.1M | 1.1% |
LONALeonaBio, Inc. | 149.3K | New | $1.4M | 0.7% |
MAZEMaze Therapeutics, Inc. | 43.8K | New | $1.3M | 0.7% |
CRVSCorvus Pharmaceuticals, Inc. | 70.4K | New | $1.1M | 0.6% |
SGMTSagimet Biosciences Inc. | 125.9K | New | $973K | 0.5% |
